Didanosine once daily: Potential for expanded use

AIDS

Volumn 14, Issue 16, 2000, Pages 2421-2428

  Pollard, Richard B ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Antiretroviral therapy; Combination therapy; Didanosine; Dosing

Indexed keywords

2',3' DIDEOXYADENOSINE TRIPHOSPHATE; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LACTIC ACIDOSIS; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS LOAD; WEIGHT GAIN;

ANTI-HIV AGENTS; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; HYDROXYUREA; LIVER; PANCREATITIS; PERIPHERAL NERVOUS SYSTEM DISEASES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0033739807     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200011100-00002     Document Type: Review

References (57)

1. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
3. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
4. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up
5. A randomized, doubleblind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
6. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
7. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
8. Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine
9. Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides
10. Once-daily administration of 2(,3(-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial
11. Didanosine in the treatment of AIDS and AIDS-related complex: A critical appraisal of the dose and frequency of administration
12. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine
13. Comparison of once- and twice-daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team
14. Didanosine administered once daily: Interim results of a randomised double blind study
15. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease
16. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: The Inter-Company Collaboration Protocol
17. Pharmacological considerations in antiretroviral therapy
18. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection
19. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex
20. Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents
21. Impact of bioavailability on determination of the maximal tolerated dose of 2(,3(-dideoxyinosine in phase I trials
22. Didanosine once daily: An overview
23. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals
24. 2',3'-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial
25. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: Analysis of activity and toxicity profiles
26. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily
27. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients
28. A randomized, double-blind, placebo-controlled trial of lamivudine (3TC) in combination with zidovudine (ZDV), stavudine (d4T), or didanosine (ddl) in treatment naive patients
29. A pilot study of the combination of stavudine (d4T) and didanosine (ddl) in patients with less than 350 CD4/mm3 and who are not eligible for a treatment with ZDV
30. Study HIV-NAT 002: The safety and efficacy of didanosine (ddl) +/- stavudine (d4T) in high/low dose combinations in an antiretroviral therapy naive Thai adult population with CD4 counts 150-350/mm3 and predominantly infected with HIV-1 clade E
31. Combination therapy with stavudine and didanosine
32. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection
33. Safety and antiretroviral effects of combined didanosine and stavudine in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3
34. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection
35. Once-daily administration of didanosine with anti-retroviral zidovudine in previously untreated patients
36. Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group
37. Once daily administration of DDL in combination with D4T among naive HIV infected patients
38. The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients with human immunodeficiency virus
39. Genotypic analysis and phenotypic susceptibility of HIV-1 isolates from patients treated with stavudine (d4T)-didanosine (ddl) combination
40. Susceptibilities of HIV-1 isolates derived from patients treated with didanosine (ddl) and stavudine (d4T) in combination
41. An open randomized study comparing d4T plus ddl and nevirapine (QD) vs d4T plus ddl and nevirapine (BID) in antiretroviral naive chronic HIV-1 infected patients in very early stages (Spanish SCAN Study)
42. The VIRGO Trial: d4T/ddl (qd)/nevirapine (bid or qd) in antiretroviral-naive HIV-1-infected patients - A convenient and potent regimen
43. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: Preliminary safety and efficacy results. VIRGO Study Team
44. The Atlantic Study: A randomized open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data
45. Once-daily therapy (NVP/ddl/3TC) for the IVDU HIV-infected population of the Frankfurt HIV-Cohort
46. Virological response to once-daily protease inhibitor (PI) sparing regimen (DDL, 3TC, NVP) after successful PI-containing therapies
47. Nevirapine (NVP) + didanosine (DDL) + lamivudine (3TC) - First experience with a once-daily dosing antiretroviral combination therapy
48. Stavudine (d4T), didanosine (ddl), and nelfinavir combination therapy in pretreated HIV-patients: Antiviral effect and safety in an ongoing study
49. Nelfinavir, didanosine and stavudine in HIV-infected drug users enrolled in opiate substitution programs at four outpatient clinics - The Zurich Prometheus Study
50. Short-term efficacy and safety of DDL and 3TC both once daily plus indinavir BID
51. DDL once daily vs. twice daily alone and also with hydroxyurea once daily
52. Randomized trial of continued indinavir (IDV)/ZDV/3TC vs. switch to IDV/ddl/d4T or IDV/ddl/d4T + hydroxyurea in patients with viral suppression
53. A comparison of d4T, ddl and indinavir (IDV) with ZDV, 3TC and IDV a the initial treatment of HIV-1: Selection of thymidine analog regimen therapy (START II)
54. Incidence of neuropathy in HIV-infected patients taking monotherapy vs. combination therapy with didanosine, stavudine, and hydroxyurea
55. Peripheral neuropathy with nucleoside antiretrovirals. Risk factors, incidence and management
56. Potential factors affecting adherence with HIV therapy